Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.4%
- Check21 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check35 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.5%
- Check42 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check64 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.